Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 473-478

  Bookman, Michael A ^a   McMeekin, D Scott ^b   Fracasso, Paula M ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Chemotherapy; Ovarian cancer; Sequential doublets; Topotecan

Indexed keywords

CARBOPLATIN; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 33750167943     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.03.014     Document Type: Article

References (20)

1. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
2. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
3. du Bois A., Luck H.J., Meier W., Adams H.P., et al., Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
4. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86 (1994) 1517-1524
5. Ma J., Maliepaard M., Nooter K., et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41 (1998) 307-316
6. Romanelli S., Perego P., Pratesi G., Carenini N., Tortoreto M., and Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41 (1998) 385-390
7. Ten Bokkel Huinink W., Gore M., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
8. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
9. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 18 (2000) 1062-1067
10. Bookman M.A., Malmström H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
11. Markman M., Blessing J.A., Alvarez R.D., Hanjani P., Waggoner S., and Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 77 (2000) 112-115
12. Miller D.S., Blessing J.A., Lentz S.S., and McMeekin D.S. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 98 (2003) 1664-1669
13. Hochster H., Wadler S., Runowicz C., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy: New York Gynecologic Oncology Group. J Clin Oncol 17 (1999) 2553-2561
14. Rowinsky E.K., Kaufmann S.H., Baker S.D., et al. Sequences of topotecan and cisplatin: phase I pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 14 (1996) 3074-3084
15. de Jonge M.J., Loos W.J., Gelderblom H., et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18 (2000) 2104-2115
16. Sorensen M., Jensen P.B., Herrstedt J., Hirsch F.R., and Hansen H.H. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol 11 (2000) 829-835
17. Hoskins P., Eisenhauer E., Vergote I., et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 18 (2000) 4038-4044
18. Gordon A.N., Hancock K.C., Matthews C.M., et al. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecol Oncol 85 (2002) 129-135
19. Gordon A.N., Asmar L., Messing M.J., et al. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 94 (2004) 533-539
20. Bowman A., Rye T., Ross G., Wheatley A., and Smyth J.F. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. J Clin Oncol 19 (2001) 3255-3259